AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28407492
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of anticoagulation in patients without RVT and negative D-dimer
Trial: 28408121
Drug: Live attenuated
RxNorm normalized name: mumps, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live attenuated influenza vaccine (LAIV4)
Trial: 28408462
Drug: CD19 CAR
RxNorm normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19 CAR T cells of defined formulation and dose
Trial: 28410572
Drug: Internal fixation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal fixation with prophylactic antibiotics (intra-operative: 92.1%, post-operative: 96.8%)
Trial: 28410572
Drug: Internal fixation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal fixation with antibiotics prescribed for an average of 8.3 days for closed fractures and 9.1 days for open fractures
Trial: 28413427
Drug: RSV F
RxNorm normalized name: Respiratory syncytial virus fusion protein.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) administered concurrently with TIV
Trial: 28413427
Drug: RSV F
RxNorm normalized name: Respiratory syncytial virus fusion protein.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant)
Trial: 28413427
Drug: RSV F
RxNorm normalized name: Respiratory syncytial virus fusion protein.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV F nanoparticle vaccine (adjuvanted)
Trial: 28413427
Drug: RSV F
RxNorm normalized name: Respiratory syncytial virus fusion protein.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSV F nanoparticle vaccine co-administered with TIV
Trial: 28415102
Drug: Fetuin-A level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetuin-A level ≤0.53 g/L
Trial: 28415102
Drug: Fetuin-A level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fetuin-A level >0.53 g/L
Trial: 28416015
Drug: Augmentation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmentation therapy (AT)
Trial: 28416015
Drug: No augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No augmentation therapy (AT)
Trial: 28416221
Drug: Ombitasvir 25
RxNorm normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, plus dasabuvir 250 mg for 8 weeks
Trial: 28416559
Drug: Nitroglycerin-based catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin-based catheter lock solution (15 or 30 μg/ml of nitroglycerin in combination with 4% sodium citrate and 22% ethanol)
Trial: 28416559
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard care (saline or heparin flush)
Trial: 28417284
Drug: Voxtalisib 70
RxNorm normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxtalisib 70 mg QD
Trial: 28417284
Drug: Voxtalisib 50
RxNorm normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxtalisib 50 mg BID
Trial: 28417284
Drug: Voxtalisib 60
RxNorm normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxtalisib 60 mg QD (MTD)
Trial: 28417284
Drug: Voxtalisib 40
RxNorm normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxtalisib 40 mg BID (MTD)
Trial: 28417284
Drug: Voxtalisib (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voxtalisib (all doses)
Trial: 28417296
Drug: DPP4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP4 inhibitors (saxagliptin)
Trial: 28420281
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) during hospitalization for STEMI
Trial: 28420281
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) during hospitalization for NSTEMI
Trial: 28420281
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) during hospitalization for UA
Trial: 28420281
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) at discharge for STEMI
Trial: 28420281
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) at discharge for NSTEMI
Trial: 28420281
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) at discharge for UA
Trial: 28420664
Drug: Intravenous iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous iron administration according to hospital's preoperative pathway
Trial: 28421334
Drug: Pharmacological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological treatment for at least 8 weeks
Trial: 28422751
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccine (DC vaccine) injected intradermally in high doses over 2 years
Trial: 28422751
Drug: Dendritic cell
RxNorm normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dendritic cell vaccine (DC vaccine)
Trial: 28422758
Drug: Regorafenib 80
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Regorafenib 80 mg daily plus cetuximab 200 mg/m2 loading dose, followed by 150 mg/m2 every week
Trial: 28423296
Drug: Eltrombopag plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag plus standard immunosuppressive therapy (cohort 1: day 14 to 6 months)
Trial: 28423296
Drug: Eltrombopag plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag plus standard immunosuppressive therapy (cohort 2: day 14 to 3 months)
Trial: 28423296
Drug: Eltrombopag plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag plus standard immunosuppressive therapy (cohort 3: day 1 to 6 months)
Trial: 28423296
Drug: Eltrombopag plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag plus standard immunosuppressive therapy (combined cohorts)
Trial: 28423296
Drug: Eltrombopag plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag plus standard immunosuppressive therapy
Trial: 28424071
Drug: Imatinib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib (400 mg per day)
Trial: 28424085
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with antibiotics
Trial: 28424085
Drug: Less drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less drug pressure
Trial: 28424891
Drug: Selumetinib plus
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib plus Erlotinib (100 mg QD)
Trial: 28424891
Drug: Selumetinib plus
RxNorm normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib plus Temsirolimus (25 mg once weekly)
Trial: 28426120
Drug: Olaratumab 20
RxNorm normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity.
Trial: 28426811
Drug: Oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral azithromycin (if PCT <0.5 ng/ml)
Trial: 28426811
Drug: Levofloxacin (if
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (if PCT ≥0.5 ng/ml)
Trial: 28427434
Drug: AdCD40L gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: AdCD40L gene therapy
Trial: 28428158
Drug: Mobile health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile health intervention (smartphone app) for medication and symptom management
Trial: 28428225
Drug: Empagliflozin treatment
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin treatment for 2 days
Trial: 28428225
Drug: Empagliflozin treatment
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin treatment for 14 days
Trial: 28428882
Drug: Immunotherapy treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immunotherapy treated mice
Trial: 28428882
Drug: Patients undergoing
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients undergoing systemic high dose IL-2
Trial: 28428884
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg twice daily and ipilimumab 3 mg/kg every 3 weeks
Trial: 28429083
Drug: Fully implantable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fully implantable treprostinil infusion pump
Trial: 28432691
Drug: Tenapanor 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenapanor 15 mg twice daily over 4 days
Trial: 28432691
Drug: Cefadroxil 500
RxNorm normalized name: cefadroxil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 500 mg for 1 day
Trial: 28432691
Drug: Cefadroxil 500
RxNorm normalized name: cefadroxil 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefadroxil 500 mg and Tenapanor 15 mg on day 5
Trial: 28433924
Drug: 50-mg deuterium-labeled
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50-mg deuterium-labeled methyl d9-TMAO (d9-TMAO)
Trial: 28434648
Drug: Nivolumab 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab 3 mg/kg every 2 weeks (dose-expansion phase)
Trial: 28434648
Drug: Nivolumab (dose-escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (dose-escalation phase)
Trial: 28434702
Drug: Telmisartan, 10
RxNorm normalized name: Amlodipine Besylate-Telmisartan, 10 mg-40 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan, 10 mg/kg/d in chow
Trial: 28434702
Drug: GW9662, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GW9662, 3 mg/kg/d through oral gavage
Trial: 28434702
Drug: AT1a KO
RxNorm normalized name: niacin
DrugBank: Niacin (DB00627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT1a KO mice (no treatment mentioned)
Trial: 28434944
Drug: rVSV-ZEBOV (highest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rVSV-ZEBOV (highest dose cohort)
Trial: 28436937
Drug: BPS804 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BPS804 (5, 10, and 20 mg/kg) administered intravenously on days 1, 15, and 29
Trial: 28437326
Drug: Intravenous fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fish oil-based lipid emulsion (FishLE) at a dosage of 1 g·kg·day until resolution of direct hyperbilirubinemia or return of enteral nutrition.
Trial: 28437326
Drug: Intravenous fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fish oil-based lipid emulsion (FishLE)
Trial: 28437488
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg single oral dose in c.662AG subjects
Trial: 28438728
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging intervention (twice daily for 6 months) tailored to participant's stage of behavior change
Trial: 28441027
Drug: β-Blocker Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β-Blocker Therapy
Trial: 28441111
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg once every 3 weeks
Trial: 28442212
Drug: Underwater ultrasound
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Underwater ultrasound therapy
Trial: 28442293
Drug: Appropriate therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Appropriate therapy (active drug against the blood isolate started in the first 5 days after infection)
Trial: 28442293
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (more than one active drug) among those receiving appropriate therapy
Trial: 28442293
Drug: Monotherapy (only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (only one active drug) among those receiving appropriate therapy
Trial: 28442293
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy in high-mortality-score stratum
Trial: 28442293
Drug: Monotherapy in
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy in high-mortality-score stratum
Trial: 28442293
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy in low-mortality-score stratum
Trial: 28442293
Drug: Monotherapy in
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy in low-mortality-score stratum
Trial: 28444114
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg/day, orally) plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Trial: 28444114
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Trial: 28444156
Drug: Fractional intradermal
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional intradermal doses of the inactivated poliovirus vaccine (ID fIPV)
Trial: 28446181
Drug: NMES applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NMES applied to agonist muscles
Trial: 28446244
Drug: Further antiepileptic
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further antiepileptic drugs (AED)
Trial: 28446495
Drug: High-volume energy
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume energy drink (946 mL, 320 mg caffeine)
Trial: 28446495
Drug: Caffeinated control
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeinated control drink (320 mg caffeine)
Trial: 28448562
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (ETN, ADL, IFX)
Trial: 28448594
Drug: HIVconsv vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIVconsv vaccines
Trial: 28448662
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection in arm B (n=60)
Trial: 28448662
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with FLOT in arm C (n=127)
Trial: 28448662
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with FLOT followed by surgery in arm B (n=36 who proceeded to surgery)
Trial: 28449090
Drug: Acute alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute alcohol consumption (mean BAC 0.85 g/kg)
Trial: 28449352
Drug: Ziconotide as
RxNorm normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ziconotide as the first agent in pump (FIP+)
Trial: 28449352
Drug: Not first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not first intrathecal agent in pump (FIP-)
Trial: 28449674
Drug: Exclusive chemotherapy
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exclusive chemotherapy
Trial: 28450351
Drug: Adenosine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adenosine (25 μg/kg; 1.5 mg if ≥60 kg)
Trial: 28450894
Drug: Peginterferon beta-1a
RxNorm normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon beta-1a 125 mcg every 2 weeks
Trial: 28453692
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks for up to 2 years or until progression or unacceptable toxicity
Trial: 28453702
Drug: Pre-treatment in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment in vitro responses of immune biomarkers to TLR8 stimulation
Trial: 28454793
Drug: Use of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of adjunctive protective pelvic drapes
Trial: 28457953
Drug: IFN-α treatment
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α treatment (recombinant human IFN-α-2b injections administered subcutaneously 2 to 3 times per week for 6 months)
Trial: 28457953
Drug: IFN-α treatment
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-α treatment
Trial: 28458770
Drug: Novel Herbal-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel Herbal-based Cream
Trial: 28460039
Drug: Elevated high-sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated high-sensitivity cardiac troponin T (hsTnT) levels (>14 ng/L)
Trial: 28460039
Drug: Detectable hsTnT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detectable hsTnT levels (5-14 ng/L)
Trial: 28460039
Drug: Undetectable hsTnT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undetectable hsTnT levels (<5 ng/L)
Trial: 28461396
Drug: Pembrolizumab, 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, dexamethasone 40 mg weekly
Trial: 28464732
Drug: Probenecid (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (250 mg twice a day for 1 week, followed by 500 mg twice a day for 3 weeks)
Trial: 28465300
Drug: Ticagrelor 90
RxNorm normalized name: ticagrelor 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor 90 mg orally twice a day for 10 days
Trial: 28465300
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg orally once a day for 10 days
Trial: 28465370
Drug: Ramucirumab 6
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 6 mg/kg every 2 weeks
Trial: 28465370
Drug: Ramucirumab 10
RxNorm normalized name: ramucirumab 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramucirumab 10 mg/kg every 3 weeks
Trial: 29508095
Drug: Ramucirumab 8
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab 8 mg/kg every 2 weeks
Trial: 28465824
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy according to the School of Manual Therapy Utrecht (MTU)
Trial: 28466686
Drug: Pre-operative concomitant
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative concomitant hyperfractionated radiotherapy (HART) with co-administration of 5-fluorouracil (5FU), total dose 42 Gy in 28 fractions of 1.5 Gy, two times daily.
Trial: 28468797
Drug: selinexor, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: selinexor, 3 to 80 mg/m²
Trial: 28468895
Drug: Vitamin B-6
RxNorm normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin B-6 supplementation, dosage and duration not available
Trial: 28468947
Drug: Intratumoral Injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intratumoral Injection